Table of Contents
Overview
New York, NY – June 25, 2025 – Global Immunodiagnostics Market size is expected to be worth around US$ 44.9 Billion by 2034 from US$ 21.6 Billion in 2024, growing at a CAGR of 7.6% during the forecast period from 2025 to 2034. In 2024, North America led the market, achieving over 45.6% share with a revenue of US$ 9.8 Billion.
The global immunodiagnostics market is poised for steady expansion due to increasing demand for early disease detection and personalized treatment approaches. As of 2024, the market is witnessing accelerated adoption of advanced immunoassay platforms across hospitals, diagnostic laboratories, and point-of-care settings. Immunodiagnostic techniques, which rely on antigen-antibody reactions to detect diseases, continue to play a crucial role in identifying infectious diseases, autoimmune disorders, and cancer biomarkers.
Rising global disease burden and supportive government initiatives are propelling the need for accurate, non-invasive diagnostics. According to the World Health Organization (WHO), non-communicable diseases account for over 70% of deaths worldwide, highlighting the importance of reliable diagnostic tools. Additionally, the growing prevalence of conditions such as hepatitis, HIV, and tuberculosis has led to increased immunoassay testing volumes in both high- and low-income regions.
Technological advancements in chemiluminescence assays, ELISA, and lateral flow tests are enhancing test sensitivity and turnaround time. Furthermore, integration of automated platforms with digital health records is improving workflow efficiency in clinical settings. Companies are also expanding R&D efforts to develop multiplexed assays for simultaneous biomarker detection, addressing the need for comprehensive diagnostic solutions. With rising healthcare expenditures and public health awareness, the immunodiagnostics market is expected to witness continued investment and innovation through the next decade.
Key Takeaways
- Market Size: The global immunodiagnostics market is projected to reach approximately USD 44.9 Billion by 2034, rising from USD 21.6 Billion in 2024.
- Market Growth: The market is expected to expand at a compound annual growth rate (CAGR) of 7.6% during the forecast period from 2025 to 2034.
- Product Analysis: Reagents and consumables constitute the largest product category, accounting for an estimated 45.6% share of the total market in 2024.
- Technology Analysis: The ELISA (enzyme-linked immunosorbent assay) technique remains the dominant technology, representing approximately 36.4% of the market share.
- Application Analysis: Infectious disease testing leads the application segment, holding around 31.2% of the overall market in 2024.
- End-Use Analysis: Hospitals emerged as the primary end-use segment, contributing approximately 34.5% to the total market share.
- Regional Analysis: North America dominated the global immunodiagnostics market in 2024, capturing over 45.6% share, with regional revenue reaching USD 9.8 billion.
Segmentation Analysis
- Product Analysis: The immunodiagnostics market includes reagents and consumables, instruments, software, and services. Reagents and consumables dominate with 45.6% market share in 2024, driven by ongoing demand for assay kits and buffer solutions. Instruments, such as analyzers, support lab automation. Software enables data processing and ensures compliance. Services, including calibration and training, are vital for maintaining system performance. These segments collectively support efficient diagnostics across clinical, academic, and research environments.
- Technology Analysis: The market is segmented by technology into ELISA, CLIA, Fluorescent Immunoassay, RIA, and Rapid Test. ELISA leads with 36.4% share, favored for its reliability and broad diagnostic use. CLIA is gaining popularity for its speed and accuracy in hormone testing. Fluorescent assays are adopted in point-of-care settings. While RIA’s use is declining due to radiation concerns, it remains in specialized labs. Rapid Tests continue expanding, especially in infectious disease and home-based diagnostics.
- Application Analysis: Immunodiagnostics are applied in Infectious Diseases, Oncology, Endocrinology, Hepatitis, Bone & Mineral, Autoimmunity, and Others. Infectious Diseases dominate with 31.2% share due to global prevalence of illnesses like COVID-19 and TB. Oncology and Endocrinology see strong demand from rising cancer and hormone disorders. Hepatitis and Retrovirus testing maintain steady use, while Bone & Mineral applications grow with aging populations. Autoimmunity diagnostics and broader categories like allergies are also expanding steadily.
- End User Analysis: By end-user, the market is segmented into Hospitals, Clinical Laboratories, Academic and Research Institutes, and the Pharmaceutical and Biotechnology Industry. Hospitals lead with 34.5% share, benefiting from high patient volume and need for quick diagnostics. Clinical labs follow, driven by outsourced testing and private lab growth. Academic institutions support R\&D and biomarker exploration. Pharma and biotech firms rely on immunodiagnostics for drug discovery, safety assessments, and clinical validation, contributing to market expansion.
Market Segments
By Product
- Reagents and Consumables
- Instruments
- Software and Services
By Technology
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Chemiluminescence Immunoassay (CLIA)
- Fluorescent Immunoassay
- Radioimmunoassay (RIA)
- Rapid Test
By Application
- Infectious Diseases
- Oncology and Endocrinology
- Hepatitis and Retrovirus
- Bone and Mineral
- Autoimmunity
- Others
By End User
- Hospitals
- Clinical Laboratories
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Industry
Regional Analysis
In 2024, North America led the global immunodiagnostics market with a dominant 45.6% share, valued at approximately USD 9.8 billion. This leadership is supported by advanced healthcare infrastructure, high diagnostic testing volumes, and widespread adoption of automated immunoassay platforms. The region benefits from elevated healthcare spending and robust insurance coverage.
Rising prevalence of chronic and infectious diseases responsible for 70% of U.S. deaths, according to the CDC—further drives demand. Preventive health screenings, supportive reimbursement frameworks, and active public health surveillance initiatives continue to strengthen North America’s position in the global market.
Emerging Trends
- Expansion of Point-of-Care Testing: The range of in vitro diagnostic products has grown substantially, with over 40 000 tests now available globally. Point-of-care immunodiagnostic assays can be performed near patients—outside central labs—and are increasingly used to speed up treatment decisions and reduce costs in settings with limited infrastructure.
- Large-Scale Outbreak Response Deployments: In April 2024, more than 1.2 million rapid cholera diagnostic tests were shipped to 14 high-risk countries in what WHO termed the largest-ever global deployment. This reflects a shift toward using immunodiagnostic rapid tests not just for individual diagnosis but for real-time surveillance during epidemics.
- Strengthened Oversight of Laboratory-Developed Tests (LDTs): As of May 6, 2024, the U.S. Food and Drug Administration finalized a rule explicitly clarifying that all in vitro diagnostic products—including those developed in clinical labs—are regulated medical devices. This regulatory tightening is expected to standardize performance and safety requirements across immunodiagnostic assays.
- Adoption of Multiplex Immunoassays for Surveillance: Multiplex formats that detect multiple antibodies simultaneously are becoming more common. For example, a CDC-validated HIV-1 multiplex incidence assay identified 71 % of recent infections (≤3 months since seroconversion) in a 2016 study, demonstrating its utility for tracking transmission trends and evaluating intervention programs.
- Growth in Electrochemiluminescence-Based Assays: Between 2023 and early 2024, FDA approved multiple ECLIA (electrochemiluminescence immunoassay) tests for hepatitis viruses such as Anti-HCV II and HBsAg II—undergoing standard 10-month reviews with goal dates in February 2024. This surge underscores a broader move toward high-sensitivity serological platforms in clinical laboratories.
Use Cases
- COVID-19 Seroprevalence Surveys: During the pandemic, CDC leveraged antibody tests to estimate past infection rates. A 2020–2021 study in Mississippi found that seroprevalence among young persons rose dramatically, informing public health strategies for vaccine rollout and non-pharmaceutical interventions.
- Monitoring HIV Transmission: Multiplex HIV immunoassays have been used to infer recent infection trends. In one study, 71 % of individuals seroconverting within three months were correctly identified, enabling health authorities to assess the impact of treatment and prevention efforts in real time.
- Hepatitis B Surveillance: Serological testing for hepatitis B core antibody (anti-HBc) provides insight into population exposure. Data from a nationally representative CDC study showed a doubling of anti-HBc prevalence among persons reporting injection drug use between periods, guiding targeted prevention initiatives.
- Blood-Donor Screening: In 2023 alone, FDA cleared at least five new immunoassays for blood-borne pathogens—such as Cytomegalovirus, syphilis, HIV, and hepatitis viruses—enhancing the safety of the blood supply and reflecting the critical role of immunodiagnostics in transfusion medicine.
Conclusion
The global immunodiagnostics market is experiencing robust growth, driven by rising disease prevalence, advancements in assay technologies, and the expanding role of point-of-care diagnostics. Increasing investment in high-sensitivity platforms, regulatory standardization, and the use of multiplex testing for surveillance are enhancing diagnostic precision and public health response.
With a projected value of USD 44.9 billion by 2034 and significant regional momentum in North America, the market is set for sustained expansion. Broad applications across infectious disease monitoring, chronic condition management, and blood safety further reinforce immunodiagnostics as a vital component of modern healthcare systems globally.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
